Dr. Abi-Jaoudeh Discusses Potential of Immunotherapy in Advanced HCC

Nadine Abi-Jaoudeh, MD
Published: Thursday, Apr 20, 2017



Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma (HCC).

Immunotherapy, and the combination of immunotherapy with locoregional therapy, could be effective in the field of advanced HCC, says Abi-Jaoudeh.

Currently, sorafenib (Nexavar) is the only FDA-approved frontline treatment for HCC. Abi-Jaoudeh says that leaves a huge space for combinations of immunotherapy and locoregional therapy to flourish.
 

<<< View more from the 2017 International Liver Congress



Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma (HCC).

Immunotherapy, and the combination of immunotherapy with locoregional therapy, could be effective in the field of advanced HCC, says Abi-Jaoudeh.

Currently, sorafenib (Nexavar) is the only FDA-approved frontline treatment for HCC. Abi-Jaoudeh says that leaves a huge space for combinations of immunotherapy and locoregional therapy to flourish.
 

<<< View more from the 2017 International Liver Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x